down arrow

Nautilus Biotechnology, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US63909J1088
USD
2.07
0.09 (4.55%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.002.18

52 Week

0.622.53
Valuation
Technical
Day's Volume

CASH

313.74 k

Shareholding (Mar 2025)

FII

0.44%

Held by 24 FIIs

DII

72.49%

Held by 12 DIIs

Promoter

21.03%

How big is Nautilus Biotechnology, Inc.?

22-Jun-2025

As of Jun 18, Nautilus Biotechnology, Inc. has a market capitalization of 88.38 million, with net sales of 0.00 million and a net profit of -68.66 million over the latest four quarters. The company reported shareholder's funds of 208.73 million and total assets of 242.74 million as of Dec 24.

Market Cap: As of Jun 18, Nautilus Biotechnology, Inc. has a market capitalization of 88.38 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Nautilus Biotechnology, Inc. reported net sales of 0.00 million and a net profit of -68.66 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 208.73 million and total assets of 242.74 million.

Read More

What does Nautilus Biotechnology, Inc. do?

22-Jun-2025

Nautilus Biotechnology, Inc. is a blank check company targeting business combinations in the healthcare sector, particularly in life sciences and medical technology. As of March 2025, it has a market cap of $88.38 million and reported a net profit loss of $17 million.

Overview: <BR>Nautilus Biotechnology, Inc. is a blank check company focused on effecting business combinations in the healthcare industry, particularly within the life sciences and medical technology sectors, and operates in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 88.38 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.69 <BR>Return on Equity: -35.31% <BR>Price to Book: 0.45 <BR><BR>Contact Details: <BR>Address: 51 Astor Place, 10Th Floor, NEW YORK NY: 10003 <BR>Tel: 1 212 2842300

Read More

Is Nautilus Biotechnology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Nautilus Biotechnology, Inc. shows a mildly bearish trend, with mixed technical indicators and significant underperformance, having a year-to-date return of -56.61% compared to the S&P 500's 12.22%.

As of 10 September 2025, the technical trend for Nautilus Biotechnology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis. The RSI shows bearish momentum weekly while being bullish monthly. Moving averages indicate a mildly bearish trend on a daily basis. Overall, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.61% versus the S&P 500's 12.22%, and a one-year return of -74.60% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 89 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

-36.27%

stock-summary
Price to Book

0.49

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
223.94%
0%
223.94%
6 Months
169.6%
0%
169.6%
1 Year
-5.05%
0%
-5.05%
2 Years
-29.35%
0%
-29.35%
3 Years
16.29%
0%
16.29%
4 Years
-59.09%
0%
-59.09%
5 Years
-80.02%
0%
-80.02%

Nautilus Biotechnology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Nautilus Biotechnology, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Nautilus Biotechnology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis. The RSI shows bearish momentum weekly while being bullish monthly. Moving averages indicate a mildly bearish trend on a daily basis. Overall, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.61% versus the S&P 500's 12.22%, and a one-year return of -74.60% compared to 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-239.19%
EBIT to Interest (avg)
-68.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
50.53%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.50
EV to EBIT
0.48
EV to EBITDA
0.56
EV to Capital Employed
-0.63
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-35.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 21 Schemes (6.04%)

Foreign Institutions

Held by 24 Foreign Institutions (0.44%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 16.67% vs -13.92% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.50",
          "val2": "-19.20",
          "chgp": "19.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-18.00",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.15% vs -10.02% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-75.10",
          "val2": "-70.40",
          "chgp": "-6.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.80",
          "val2": "-63.70",
          "chgp": "-11.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.50
-19.20
19.27%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.00
-18.00
16.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 16.67% vs -13.92% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-75.10
-70.40
-6.68%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-70.80
-63.70
-11.15%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.15% vs -10.02% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Nautilus Biotechnology, Inc. stock-summary
stock-summary
Nautilus Biotechnology, Inc.
Pharmaceuticals & Biotechnology
ARYA Sciences Acquisition Corp III is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It intends to focus on entities operating in the healthcare industry, particularly the life sciences and medical technology sectors. It has not commenced any operations.
Company Coordinates stock-summary
Company Details
51 Astor Place, 10Th Floor , NEW YORK NY : 10003
stock-summary
Tel: 1 212 2842300
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."